Base Year
Historical Year
Forecast Year
The neuroblastoma market size is expected to grow at a CAGR of 2.4% during the forecast period of 2024-2032, driven by the increasing incidence of cancer and rising preference for personalised medicine across the major markets.
Neuroblastoma is an extracranial tumor, originating from neural crest progenitor cells. It has a high prevalence in children. 37% of the overall patients are infants, and around 90% of the patients are younger than 5 years of age. The United States witnesses around 650 new cases annually, with a prevalence of 1 case per 7,000 live births.
Neuroblastoma accounts for 15% of the overall pediatric cancers. Consequently, effective treatment has been a major area of attention amongst scientists, propelling the neuroblastoma market share. While the disease can occur anywhere along the sympathetic nervous system, it majorly arises in the adrenal glands. With heterogeneity in tumor grade, stage and location, treatment modalities vary across observation, surgical interventions, chemotherapy, radiation therapy and immunotherapy.
The neuroblastoma market growth is driven by rising preference and adoption of gene therapies to offer precise and personalized treatment to patients. In November 2023, researchers at the University of Texas developed a gene therapy to pre-treat neuroblastoma tumors by expanding blood vessels surrounding a tumor. The potential treatment can be used to enhance the efficacy of drugs to regress tumor size.
| Key Trend | Impact |
Surge in Clinical Trials and Research Initiatives |
With a deeper understanding of human physiology and biotech associated technical advancements, targeted therapy, immunology, and personalized medicine have emerged as a promising treatment strategy. |
| Emphasis on Early Detection | Development of novel biomarkers and diagnostic methods, aimed at determining most effective and accurate treatment early to stop disease progression is a significant market trend. |
| Rising Collaborations to Drive Awareness | Collaborations among research institutions, pharmaceutical companies and non-profit organizations are contributing to neuroblastoma market value. Investments and awareness initiatives are expected to influence the market positively in coming years. |
| Increased Focus on Improving Quality of Life | With improvement in treatment alternatives, there is an emphasis on long-term health and prevention of tumor recurrence. This includes addressing late effects of cancer treatment such as hearing loss and developmental delays among others. |
Market Breakup by Diagnosis
The market segmentation by diagnosis includes MIBG scan, imaging, and biopsy. MIBG (Metaiodobenzylguanidine) scan is a nuclear medicine imaging technique that helps in tumor visualization throughout the body using a special camera. Imaging techniques include MRI, CT scans and ultrasounds. Biopsy helps in confirming the presence of cancerous cells and provides an insight into tumor type and characteristics.
Market Breakup by Treatment
To meet the rising neuroblastoma market demand, the market segmentation addresses the treatment landscape as well. It includes medication, surgery, chemotherapy, radiation therapy, stem cell transplantation, immunotherapy, and monoclonal antibody treatment. It varies based on grade, size, and location of tumor.
Market Breakup by End Users
Market breakup by end users constitutes hospitals, specialty clinics, surgical centers, and diagnostic centers among others. Hospitals are the most prominent alternative of tumor detection amongst patients.
Market Breakup by Region
The neuroblastoma market report covers all major markets in the regional breakup. It includes United States, EU-4 (Germany, France, Italy, and Spain), United Kingdom, Japan as well as China. United States leads the market share, owing to its well-developed infrastructure along with the presence of several key healthcare and pharmaceutical players in the region. Asia Pacific is deemed to witness substantial growth in the forecast period, which can be attributed to increasing investments to improve the healthcare infrastructure.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
| Breakup by Treatment |
|
| Breakup by Age Group |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 2.4% during the forecast period of 2024-2032, driven by increasing prevalence of cancer across the major markets.
The market demand is driven by growth in clinical trials and research initiatives, emphasis on early detection of cancer and rising public private sector collaborations to drive awareness.
The adoption of gene therapies to offer personalised and accurate treatment to patients is a major market trend. In November 2023, the University of Texas researchers developed a gene therapy to pre-treat neuroblastoma tumors by expanding blood vessels surrounding it.
Based on diagnosis, the market is divided into MIBG scan, imaging, and biopsy.
Major end users include hospitals, specialty clinics, surgical centres, diagnostic centres, and others.
Medication, surgery, chemotherapy, radiation therapy, stem cell transplantation, immunotherapy, and monoclonal antibody treatment are common treatments used to treat neuroblastoma.
The major regions of the market include the United States, Japan, China, EU-4, and the United Kingdom. EU-4 includes Germany, France, Italy, and Spain.
Key players involved in the market are Eli Lilly and Company, Bayer AG, GE Healthcare, Beckman Coulter Inc., bioMerieux, BD Biosciences, Lonza Biologics Ltd., Sanofi S.A., Pfizer Inc., Cellectar Biosciences, Baxter International Inc., APEIRON Biologics AG, United Therapeutics Corporation, Sartorious AG and MacroGenics, Inc.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share